Literature DB >> 22112735

The prevalence and antimicrobial susceptibility patterns of beta-hemolytic streptococci colonizing the throats of schoolchildren in Assam, India.

Utpala Devi1, Prasanta Kumar Borah, Jagadish Mahanta.   

Abstract

INTRODUCTION: Studies on the carriage rate of beta-hemolytic streptococci among children form an important component of public health practice to prevent disease complications such as rheumatic fever/rheumatic heart disease, nephritis, and other local or systemic infections.
METHODOLOGY: Throat swabs collected from asymptomatic schoolchildren were inoculated into appropriate media for isolation of beta-hemolytic streptococci. They were identified by standard biochemical methods and sero-grouped. Antibiotic sensitivity was evaluated using the Kirby-Bauer disk diffusion method. RESULTS AND
CONCLUSION: Beta-hemolytic streptococci were isolated from 106 (7.7%) out of the 1,384 throat swabs and Group F was the predominant sero-group isolated. The highest resistance observed among all the beta-hemolytic streptococci was to trimethoprim-sulfamethoxazole.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112735     DOI: 10.3855/jidc.1465

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  12 in total

1.  first detection of trimethoprim resistance determinant dfrG in Streptococcus pyogenes clinical isolates in India.

Authors:  René Bergmann; Vivek Sagar; D Patric Nitsche-Schmitz; Gursharan S Chhatwal
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

Review 2.  Different antibiotic treatments for group A streptococcal pharyngitis.

Authors:  Mieke L van Driel; An Im De Sutter; Hilde Habraken; Sarah Thorning; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2016-09-11

3.  Factors that cause trimethoprim resistance in Streptococcus pyogenes.

Authors:  René Bergmann; Mark van der Linden; Gursharan S Chhatwal; D Patric Nitsche-Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

4.  Pneumococcal disease in India: the dilemma continues.

Authors:  Joseph L Mathew; Sunit Singhi
Journal:  Indian J Med Res       Date:  2014-08       Impact factor: 2.375

5.  M types & toxin gene profile of group A streptococci isolated from children in Dibrugarh district of Assam, India.

Authors:  Utpala Devi; Prasanta Kumar Borah; Vinita Malik; Pratap Parida; Jagadish Mahanta
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

Review 6.  Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.

Authors:  Asha C Bowen; Jonathan R Carapetis; Bart J Currie; Vance Fowler; Henry F Chambers; Steven Y C Tong
Journal:  Open Forum Infect Dis       Date:  2017-11-02       Impact factor: 3.835

7.  Different antibiotic treatments for group A streptococcal pharyngitis.

Authors:  Mieke L van Driel; An Im De Sutter; Sarah Thorning; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2021-03-17

8.  Throat culture positivity rate and antibiotic susceptibility pattern of beta-hemolytic streptococci in children on secondary prophylaxis for rheumatic heart disease.

Authors:  Nigus Zegeye; Daniel Asrat; Yimtubezinash Woldeamanuel; Abebe Habte; Etsegenet Gedlu; Tone Tønjum; Abraham Aseffa
Journal:  BMC Infect Dis       Date:  2016-09-23       Impact factor: 3.090

9.  Burden of bacterial upper respiratory tract pathogens in school children of Nepal.

Authors:  Sangita Thapa; Shishir Gokhale; Annavarapu Laxminarasimha Sharma; Lokendra Bahadur Sapkota; Shamshul Ansari; Rajendra Gautam; Sony Shrestha; Puja Neopane
Journal:  BMJ Open Respir Res       Date:  2017-10-13

10.  Group A beta-hemolytic streptococcal pharyngitis and carriage rate among Egyptian children: a case-control study.

Authors:  Shereen Mohamed Abd El-Ghany; Abeer Ahmed Abdelmaksoud; Sally Mohamed Saber; Dalia Hosni Abd El Hamid
Journal:  Ann Saudi Med       Date:  2015 Sep-Oct       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.